ARTICLE | Clinical News
AGN-214868: Phase II started
March 14, 2011 7:00 AM UTC
Syntaxin said Allergan began a double-blind, placebo-controlled, international Phase II trial to evaluate 3,250 and 16,250 ng AGN-214868 in about 280 patients. Syntaxin said the start of Phase II tria...